← Back to Patent Explorer
US4180560A Expired / Lapsed US ⏱️ 0.0 years remaining

Inert core implant pellet

Assignee: Roche Palo Alto LLC
•
Filing: 1978-05-05
•
Granted: 1979-12-25
•
Expires: 1998-05-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A novel spherical implant pellet containing estradiol, estradiol benzoate, or mixtures thereof as the sole active ingredients which exhibits a substantially constant drug release rate over a timer period and substantially abrupt termination of drug release at the end of the time period is prepared which has an inert spherical core of a diameter of about 2-10 mm and a uniform coating of about 0.05-1 mm completely covering the core, the coating comprising about 5-99% suitable carrier and 1-95% drug. A drug may be administered at a constant rate over a chosen period by implanting the novel pellet and the release is substantially abruptly terminated at the end of said period without removing the pellet.

Inventors

  • 👤 Martin Katz
  • 👤 John S. Kent

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 17:24
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/56; A61K31/565; A61K9/14; A61K9/16; A61K9/167; A61K9/1676

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 175 words
A solid, spherical, subcutaneously implantable pellet for producing a greater than normal weight gain in ruminants, which implantable pellet exhibits a substantially constant rate of release of active agent over a given time period and an abrupt termination of drug release at the end of said time period, said pellet comprising (a) a biocompatible, inert, spherical core having a diameter of about 2 mm to about 10 mm and (b) at least one biocompatible, biosoluble coating having a substantially uniform thickness of about 0.05 mm to about 1.0 mm intimately adhering to and completely covering said inert core, the composition of said coating comprising a substantially homogeneous mixture of (i) about 5% weight to about 90% weight of estradiol, estradiol benzoate, or mixtures thereof as the sole active agent(s), and (ii) about 10% weight to about 95% weight of a pharmaceutically suitable carrier which is solely a polyethylene glycol having a molecular weight of about 3000 to about 20,000, said inert, spherical core being at at least half the diameter of said spherical, implantable pellet.
Claim 2
Dependent Claim 175 words
A solid, spherical, subcutaneously implantable pellet for producing a greater than normal weight gain in ruminants, which implantable pellet exhibits a substantially constant rate of release of active agent over a given time period and an abrupt termination of drug release at the end of said time period, said pellet comprising (a) a biocompatible, inert, spherical core having a diameter of about 2 mm to about 10 mm and (b) at least one biocompatible, biosoluble coating having a substantially uniform thickness of about 0.05 mm to about 1.0 mm intimately adhering to and completely covering said inert core, the composition of said coating comprising a substantially homogeneous mixture of (i) about 5% weight to about 90% weight of estradiol, estradiol benzoate, or mixtures thereof as the sole active agent(s), and (ii) about 10% weight to about 95% weight of a pharmaceutically suitable carrier which is solely a polyethylene glycol having a molecular weight of about 3000 to about 20,000, said inert, spherical core being at at least half the diameter of said spherical, implantable pellet.
Claim 3
Dependent Claim 17 words
The pellet of claim 1 wherein said polyethylene glycol has a molecular weight about 6000 to 7500.
Claim 4
Dependent Claim 211 words
A process for administering estradiol, estradiol benzoate, or mixtures thereof to a ruminant over a given period of time to provide a greater than normal weight gain, which process comprises subcutaneously implanting at least one spherical pellet comprising (a) a biocompatible, inert, spherical core having a diameter of about 2 mm to about 10 mm and (b) at least one biocompatible, biosoluble coating having a substantially uniform thickness of about 0.05 mm to about 1.0 mm intimately adhering to and completely covering said inert core, the composition of said coating comprising a substantially homogeneous mixture of (i) about 5% to about 90% weight of estradiol, estradiol benzoate or mixtures thereof as the sole active agent(s), and (ii) about 10% weight to about 95% weight of a pharmaceutically suitable carrier which is solely a polyethylene glycol having a molecular weight of about 3000 to about 20,000, the diameter of said inert spherical core being at least half the diameter of said spherical implantable pellet, said active agent(s) being released at a substantially constant weight-gain producing rate over said given time period, said agent(s) being substantially fully released at the end of said given time period and substantially none of said active agent(s) being released from said pellet after said given time period.
Claim 5
Dependent Claim 211 words
A process for administering estradiol, estradiol benzoate, or mixtures thereof to a ruminant over a given period of time to provide a greater than normal weight gain, which process comprises subcutaneously implanting at least one spherical pellet comprising (a) a biocompatible, inert, spherical core having a diameter of about 2 mm to about 10 mm and (b) at least one biocompatible, biosoluble coating having a substantially uniform thickness of about 0.05 mm to about 1.0 mm intimately adhering to and completely covering said inert core, the composition of said coating comprising a substantially homogeneous mixture of (i) about 5% to about 90% weight of estradiol, estradiol benzoate or mixtures thereof as the sole active agent(s), and (ii) about 10% weight to about 95% weight of a pharmaceutically suitable carrier which is solely a polyethylene glycol having a molecular weight of about 3000 to about 20,000, the diameter of said inert spherical core being at least half the diameter of said spherical implantable pellet, said active agent(s) being released at a substantially constant weight-gain producing rate over said given time period, said agent(s) being substantially fully released at the end of said given time period and substantially none of said active agent(s) being released from said pellet after said given time period.
Claim 6
Dependent Claim 18 words
The process of claim 3 wherein said polyethylene glycol has a molecular weight of about 6000 to 7500.

References Cited (Backward Citations)

US4096239A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-12-24 1983-06-25 1983-12-25 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-12-24 1987-06-25 1987-12-25 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-12-24 1991-06-25 1991-12-25 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag